CL2018001092A1 - Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico. - Google Patents

Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.

Info

Publication number
CL2018001092A1
CL2018001092A1 CL2018001092A CL2018001092A CL2018001092A1 CL 2018001092 A1 CL2018001092 A1 CL 2018001092A1 CL 2018001092 A CL2018001092 A CL 2018001092A CL 2018001092 A CL2018001092 A CL 2018001092A CL 2018001092 A1 CL2018001092 A1 CL 2018001092A1
Authority
CL
Chile
Prior art keywords
methods
compositions
treatment
ultrapure
diseases
Prior art date
Application number
CL2018001092A
Other languages
English (en)
Inventor
Zhijian Zhu
Helen Barker
Michael Yeadon
Wai Liu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2018001092A1 publication Critical patent/CL2018001092A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICION QUE COMPRENDE DIHIDRATO DE N<sup>4</sup>-(CICLOPROPILMETIL)-6-[(3R)-3-(METILAMINO)PIRROLIDIN-1-IL]PIRIMIDIN-2,4-DIAMINA TARTRATO; METODOS PARA SU PREPARACION;  FORMA DE DOSIFICACION; UN COMPRIMIDO; Y METODOS DE TRATAMIENTO DE UNA ENFERMEDAD O AFECCION MEDIADA POR H4 TAL COMO DERMATITIS, PSORIASIS Y URTICARIA, ENTRE OTRAS.
CL2018001092A 2015-10-26 2018-04-25 Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico. CL2018001092A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246482P 2015-10-26 2015-10-26
US201662329091P 2016-04-28 2016-04-28
US201662359066P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
CL2018001092A1 true CL2018001092A1 (es) 2018-08-10

Family

ID=57200025

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001092A CL2018001092A1 (es) 2015-10-26 2018-04-25 Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.

Country Status (21)

Country Link
US (2) US20190135787A1 (es)
EP (1) EP3368528A1 (es)
JP (1) JP2018531288A (es)
KR (1) KR20180067683A (es)
CN (1) CN108602801A (es)
AU (2) AU2016344627B9 (es)
BR (1) BR112018007765A2 (es)
CA (1) CA3001636A1 (es)
CL (1) CL2018001092A1 (es)
CO (1) CO2018004323A2 (es)
EC (1) ECSP18038867A (es)
HK (1) HK1252050A1 (es)
IL (1) IL258813A (es)
MX (1) MX2018005140A (es)
PE (1) PE20181364A1 (es)
PH (1) PH12018500822A1 (es)
RU (1) RU2018119104A (es)
SG (1) SG11201802676QA (es)
TW (1) TW201729810A (es)
WO (1) WO2017072131A1 (es)
ZA (1) ZA201802183B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2019073388A1 (en) * 2017-10-09 2019-04-18 Teva Pharmaceutical Industries Ltd. NEW SALT AND FORMS IN THE STRONG STATE OF ESCITALOPRAM
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP4291162A1 (en) 2021-02-10 2023-12-20 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
ES2264534T3 (es) 2002-09-06 2007-01-01 Janssen Pharmaceutica N.V. Compuestos de tienopirrolilo y furanopirrolilo y su utilizacion como ligandos del receptor histaminico h4.
KR101235116B1 (ko) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 광학활성 암로디핀 겐티세이트 염의 제조방법
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2008127359A (ja) * 2006-11-22 2008-06-05 Kowa Co アトピー性皮膚炎の予防及び／又は治療剤
US9688989B2 (en) * 2012-06-08 2017-06-27 Sensorion H4 receptor inhibitors for treating tinnitus

Also Published As

Publication number Publication date
PH12018500822A1 (en) 2018-10-01
EP3368528A1 (en) 2018-09-05
AU2016344627A1 (en) 2018-05-10
AU2016344627B2 (en) 2019-11-07
AU2020200840A1 (en) 2020-02-27
SG11201802676QA (en) 2018-05-30
AU2016344627B9 (en) 2019-11-28
ECSP18038867A (es) 2018-05-31
CA3001636A1 (en) 2017-05-04
PE20181364A1 (es) 2018-08-27
RU2018119104A (ru) 2019-11-28
BR112018007765A2 (pt) 2018-10-23
TW201729810A (zh) 2017-09-01
IL258813A (en) 2018-06-28
MX2018005140A (es) 2018-05-07
US20190135787A1 (en) 2019-05-09
US20170158671A1 (en) 2017-06-08
CO2018004323A2 (es) 2018-07-19
HK1252050A1 (zh) 2019-05-10
JP2018531288A (ja) 2018-10-25
ZA201802183B (en) 2019-02-27
KR20180067683A (ko) 2018-06-20
WO2017072131A1 (en) 2017-05-04
RU2018119104A3 (es) 2020-02-19
CN108602801A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
CL2018001092A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para sus uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2016001895A1 (es) Compuestos
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
UY35369A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
MX2016010105A (es) Derivados de nucleosido sustituidos con 4´ -difluorometilo como inhibidores de la replicacion de arn de la infuenza.
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CO2017011996A2 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
ECSP16074478A (es) Compuestos novedosos
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
CO2021001925A2 (es) Piridopirimidinas como inhibidores del receptor de histamina h4